期刊文献+

成纤维细胞生长因子23在慢性肾病脏中的检测意义 被引量:5

下载PDF
导出
摘要 2000年Yamashita等首先在小鼠体内证实了表达于丘脑腹外侧核的一个分泌蛋白FGF23.随后常染色体显性低磷酸盐性佝偻病(Autosomal dominant hypophosphatemic rickets,ADHR)协作组首次报到了ADHR与FGF23的关系,考虑本病的发生与相关基因缺失引起FGF23的过表达有关.2001年,Shimada等证实导致肿瘤相关骨软化症(Tumor-induced osteomalacia,TIO)肿瘤分泌FGF23过多的关系.十多年来,FGF23作为新发现的磷代谢调节因子备受关注,美国的慢性肾功能衰竭队列(CRIC)研究揭示了FGF23水平对慢性肾脏病(CKD)患者的预后有独立预测作用.针对FGF23的干预治疗可能是延缓CKD进展的重要措施.
出处 《中国血液净化》 2014年第9期658-660,共3页 Chinese Journal of Blood Purification
基金 国家自然科学基金(12981270408) 中华医学会临床科研专项基金首届肾脏病青年研究基金(13030300415) 江苏省"医学重点人才"项目(RC201162)资助
  • 相关文献

参考文献25

  • 1Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain[J]. Biochem Biophys Res Commun, 2000,277: 494- 498.
  • 2Autosomal dominant hypophosphataemic rickets is associ- ated with mutations in FGF23[J]. Nat Genet, 2000,26: 345-348.
  • 3Shimada T, Mizutani S, Muto T, et al. Cloning and char- acterization of FGF23 as a causative factor of tUmor- induced :steomalaeia[J]. Proc Natl head Sci U S A, 2001,98: 6500-6505.
  • 4Isakova T, Xie H, Yang W, et al. Fibroblast growth fac- tor 23 and risks of mortality and end-stage renal dis- ease in patients with chronic kidney disease[J]. JAMA, 2011, 305: 2432-2439.
  • 5Baum M, Schiavi S, Dwarakanath V, et al. Effect of fi- broblast growth factor- 23 on phosphate transport in proximal tubules[J]. Kidney Int, 2005,58: 1148-1153.
  • 6Miyamoto K, Ito :, Kuwahata M, et al. Inhibition of in- testinal sodium- dependent inorganic phosphate trans port hy fibroblast growth factor 23[J]. Ther Apher Di- al, 2005,9: 331-335.
  • 7Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in pa- tients with end- stage renal disease on hemodialysis [J]. Kidney Int, 2004,65: 1943-1946.
  • 8Kendrick J, Cheung hE, Kaufman JS, et al. FGF-23 associ- ates with death, cardiovascular events, and initiation of chronic dialysis[J]. J Am Soc Nephrol, 2011,22: 1913-1922.
  • 9Jean G, Terrat JC, Vanel T, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients[J]. Nephrol Dial Transplant, 2009, 24: 2792-2796.
  • 10Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibro-blast growth factor 23 is a risk factor for kidney transplant loss and mortality[J]. J Am Soc Nephrol, 2611,22: 956-966.

同被引文献47

  • 1朱涛.序贯结肠透析联合尿毒清颗粒治疗慢性肾脏病伴高尿酸血症的临床疗效探讨[J].世界临床医学,2017,11(2):86-86. 被引量:6
  • 2叶田增.不同血液净化方式对慢性肾病患者血清甲状旁腺素的影响[J].今日健康,2016,15(1):360-360. 被引量:3
  • 3赵水平.高密度脂蛋白的研究现状[J].中国动脉硬化杂志,2005,13(6):673-675. 被引量:22
  • 4Patel TV, Singh AK. Kidney disease outcomes quality initiati-e guidelines for bone and mineral metabolism:emerging questions. Semin Nephrol,2009,29(2) :105 -112.
  • 5Isako-a T, Xie H, Barchi - Chung A, et al. Fibroblast growth fac- tor 23 in patients undergoing peritoneal dialysis. Clin J Am SocNephrol,2011,6( 11 ) :2688 -2695.
  • 6Yokota H, Raposo JF, Chen A, et al. E-aluation of the role of FGF23 in Mineral Metabolism. Gene Regul Syst Bio, 2009,3 (3) :131 -142.
  • 7Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soe Nephro1,2007,18 (6) : 1637 - 1647.
  • 8Xu XJ, Liang XH, Hu GM, et al. Renal Function and Klotho Gene Polymorphisms among Uygur and Kazak Populations in Xinjiang, China. Med Sci Monit,2015,21 ( 1 ) :44 - 51.
  • 9Nitta K, Nagano N, Tsuchiya K. Fibroblast Growth Factor 23/ Klotho Axis in Chronic Kidney Disease. Nephron Clin Pratt, 2014,128(1) :1 - 10.
  • 10Hu MC, Shi M, Zhang J, et al. Klotho : a no-el phosphaturie sub- stance acting as an autoerine enzyme in the renal proximal tu- bule. FASEB J,2010,24(9) :3438 -3450.

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部